First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. - Wikidata - awgldk - TriplyDB

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.

http://www.wikidata.org/entity/Q46452752

about

Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data.Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.HLA-B*5701 testing to predict abacavir hypersensitivity Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.Personalized medicine approach in mycobacterial disease.Pharmacogenetics of drug hypersensitivity.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.Pharmacogenomics of adverse drug reactions: practical applications and perspectives.A multifaceted 'omics' approach for addressing the challenge of antimicrobial resistance.Comparative Analysis of Real-Time Polymerase Chain Reaction Methods to Typing HLA-B*57:01 in HIV-1-Positive Patients.Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Individualization of antiretroviral therapy.Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.Successful translation of pharmacogenetics into the clinic: the abacavir example.Drug-induced liver injury: what was new in 2008?HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.Abacavir and lamivudine combination.Leveraging Genomic Factors to Improve Benefit-Risk.Systematic review of pharmacoeconomic studies of pharmacogenomic tests.HLA and pharmacogenetics of drug hypersensitivity.Evidence and resources to implement pharmacogenetic knowledge for precision medicine.Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.Safety and Efficacy of Ziagen (Abacavir Sulfate) in HIV-Infected Korean Patients.

P2860

Q28083100-8A07018B-23A0-4D12-95FA-B64C7077ED1E Q30758299-BBDE8709-9366-4CA2-A8DA-1395134DB403 Q31118978-BDDB0618-A6C3-4299-A422-FCCECF8DA1DC Q33768961-C725F51C-13BA-476F-9C3E-D237C563732D Q33807615-7190BD65-41C3-47D4-8736-3ABAFC178699 Q34034330-8AC97266-DA6C-4BEE-B8A0-B2E8AB96882E Q34118186-546A6950-ECF9-4997-8010-24E24F1E4486 Q34131354-44CF83EA-3CD5-437B-B183-C52C93960570 Q34987138-A27D0DAD-3ACE-43FA-9C4B-E631612B103A Q35587853-F955C230-BC7B-488F-B064-CC4840424C15 Q35889793-EE3A2A8C-0174-40A7-8B68-A246D7ACEA2F Q36029478-51E892FB-076F-4731-BBEE-1D31ED6E61D9 Q36441423-25A31DC6-CDD7-4AAB-87C4-5A8164635DE5 Q37389496-5F603EA3-272F-4ACF-9B35-F0C91E2496C4 Q37436365-6BFC9177-55DF-4CA7-BFE1-6D2772466DEB Q37510856-0B133E60-6733-44A7-AE33-EF5164E749E6 Q37514235-9B5E7B31-8BA9-423D-85BF-4A572FCF9008 Q37636061-A0FCAA4A-91CC-49E9-8083-85459DFA96D5 Q37708018-5809BEC8-0D60-49FE-ACD4-3F2511D9D548 Q37814401-7BCDC6D6-5A31-4B0F-846E-040259EEF647 Q38037649-E2642D19-1825-4262-8F92-C82B75AF8050 Q39173298-9AAF56AE-591B-4849-B7CD-7794FE7401D1 Q41000900-C8CAB313-2779-4C93-B3E4-78D3D3371855 Q42259925-D9A5844C-B130-47D9-8779-7B249E458EF0

P2860

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.

http://www.wikidata.org/entity/Q46452752

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

First large, multicenter, open ...... rsensitivity in North America.

@en

First large, multicenter, open ...... rsensitivity in North America.

@nl

type

label

First large, multicenter, open ...... rsensitivity in North America.

@en

First large, multicenter, open ...... rsensitivity in North America.

@nl

prefLabel

First large, multicenter, open ...... rsensitivity in North America.

@en

First large, multicenter, open ...... rsensitivity in North America.

@nl

P1433

Q46452752-92377409-D2E3-497B-B972-F55C46B54566

P1476

Q46452752-FE1B027D-FABA-416D-B9BC-079556DDC3D5

P2093

Q46452752-0612916F-818A-47E9-82E2-126EC90035A0

Q46452752-0D64274D-676A-4405-A013-28505EDC63CD

Q46452752-29560EEE-6BE2-43BD-8186-E9488EFD3076

Q46452752-67682BAB-A0B1-4651-95C6-8025255CDEA8

Q46452752-6C556CA4-CB0B-40F6-9E49-11610A80B006

Q46452752-6E57D106-FDCA-43C4-B523-36411C240F85

Q46452752-7F10EA54-2FD5-4D8A-9C1F-20EBDE3C651A

Q46452752-946E2BDB-E14E-4BCA-A3CB-50B6B08641F7

Q46452752-96628B63-FD9C-4437-98EC-54259EA1EB57

Q46452752-C08659D7-7938-4A84-B71B-74183CA84D63

P304

Q46452752-2BD98E3E-850D-4660-B385-DD4169A123C1

P31

Q46452752-2F003FBB-61EB-43D6-A074-03C0D8B72864

P356

Q46452752-6E4BCEA3-8553-4CE2-BD3E-98D49C14CE65

P407

Q46452752-38694180-06A5-4993-A83C-EF6750C91C84

P433

Q46452752-162DB15A-5472-4706-9360-BCBF40FB279A

P478

Q46452752-13D765EB-3CFC-429A-902B-8AA7FBAD11AF

P577

Q46452752-F5923583-3E86-4847-9C2C-968A62627F6A

P698

Q46452752-F3FF815C-8AD1-46E0-81BE-A922F6E481F8

P356

QAD.0B013E32830719AA

P1433

P1476

First large, multicenter, open ...... rsensitivity in North America.

@en

P2093

Benjamin Young

http://www.w3.org/2001/XMLSchema#string

Daniel Berger

http://www.w3.org/2001/XMLSchema#string

Denise H Sutherland-Phillips

http://www.w3.org/2001/XMLSchema#string

Edwin Dejesus

http://www.w3.org/2001/XMLSchema#string

Kathleen Squires

http://www.w3.org/2001/XMLSchema#string

Mark Shaefer

http://www.w3.org/2001/XMLSchema#string

Nicholaos Bellos

http://www.w3.org/2001/XMLSchema#string

Parul Patel

http://www.w3.org/2001/XMLSchema#string

Paul Wannamaker

http://www.w3.org/2001/XMLSchema#string

Qiming Liao

http://www.w3.org/2001/XMLSchema#string

P304

1673-1675

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E32830719AA

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18670229

http://www.w3.org/2001/XMLSchema#string